BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J Pathol 2009;217:469-82. [PMID: 19148905 DOI: 10.1002/path.2499] [Cited by in Crossref: 100] [Cited by in F6Publishing: 94] [Article Influence: 7.7] [Reference Citation Analysis]
Number Citing Articles
1 Armakolas N, Armakolas A, Antonopoulos A, Dimakakos A, Stathaki M, Koutsilieris M. The role of the IGF-1 Ec in myoskeletal system and osteosarcoma pathophysiology. Critical Reviews in Oncology/Hematology 2016;108:137-45. [DOI: 10.1016/j.critrevonc.2016.11.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
2 Xie H, Mao JS, Hu WF. Insulin-Like Growth Factor 1 (IGF1) Pathway Member Polymorphisms Are Associated with Risk and Prognosis of Chondrosarcoma. Med Sci Monit 2020;26:e923853. [PMID: 32314747 DOI: 10.12659/MSM.923853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Demicco EG, Lazar AJ. Clinicopathologic Considerations: How Can We Fine Tune Our Approach to Sarcoma? Seminars in Oncology 2011;38:S3-S18. [DOI: 10.1053/j.seminoncol.2011.09.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
4 Schmid C, Ghirlanda C, Niessen M. Prevention of tumour cell apoptosis associated with sustained protein kinase B phosphorylation is more sensitive to regulation by insulin signalling than stimulation of proliferation and extracellular signal-regulated kinase. Mol Cell Biochem 2017;432:41-54. [PMID: 28316059 DOI: 10.1007/s11010-017-2996-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
5 Carter YM, Kunnimalaiyaan S, Chen H, Gamblin TC, Kunnimalaiyaan M. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther 2014;15:510-5. [PMID: 24521712 DOI: 10.4161/cbt.28015] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
6 Kolb EA, Gorlick R, Lock R, Carol H, Morton CL, Keir ST, Reynolds CP, Kang MH, Maris JM, Billups C, Smith MA, Houghton PJ. Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program. Pediatr Blood Cancer 2011;56:595-603. [PMID: 21298745 DOI: 10.1002/pbc.22741] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 4.3] [Reference Citation Analysis]
7 Rainusso N, Man TK, Lau CC, Hicks J, Shen JJ, Yu A, Wang LL, Rosen JM. Identification and gene expression profiling of tumor-initiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model. Cancer Biol Ther. 2011;12:278-287. [PMID: 21617384 DOI: 10.4161/cbt.12.4.15951] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
8 Asmane I, Watkin E, Alberti L, Duc A, Marec-Berard P, Ray-Coquard I, Cassier P, Decouvelaere AV, Ranchère D, Kurtz JE, Bergerat JP, Blay JY. Insulin-like growth factor type 1 receptor (IGF-1R) exclusive nuclear staining: a predictive biomarker for IGF-1R monoclonal antibody (Ab) therapy in sarcomas. Eur J Cancer 2012;48:3027-35. [PMID: 22682017 DOI: 10.1016/j.ejca.2012.05.009] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 8.0] [Reference Citation Analysis]
9 Santoro M, Lamhamedi-Cherradi SE, Menegaz BA, Ludwig JA, Mikos AG. Flow perfusion effects on three-dimensional culture and drug sensitivity of Ewing sarcoma. Proc Natl Acad Sci U S A 2015;112:10304-9. [PMID: 26240353 DOI: 10.1073/pnas.1506684112] [Cited by in Crossref: 67] [Cited by in F6Publishing: 56] [Article Influence: 9.6] [Reference Citation Analysis]
10 Riedel RF. Targeted agents for sarcoma: is individualized therapy possible in such a diverse tumor type? Semin Oncol 2011;38 Suppl 3:S30-42. [PMID: 22055970 DOI: 10.1053/j.seminoncol.2011.09.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
11 Bernardini G, Laschi M, Geminiani M, Santucci A. Proteomics of osteosarcoma. Expert Rev Proteomics 2014;11:331-43. [PMID: 24654989 DOI: 10.1586/14789450.2014.900445] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
12 Giorgi C, Boro A, Rechfeld F, Lopez-Garcia LA, Gierisch ME, Schäfer BW, Niggli FK. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1. Oncotarget 2015;6:28895-910. [PMID: 26336820 DOI: 10.18632/oncotarget.5000] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
13 Olmos D, Tan DS, Jones RL, Judson IR. Biological rationale and current clinical experience with anti-insulin-like growth factor 1 receptor monoclonal antibodies in treating sarcoma: twenty years from the bench to the bedside. Cancer J 2010;16:183-94. [PMID: 20526094 DOI: 10.1097/PPO.0b013e3181dbebf9] [Cited by in Crossref: 53] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
14 Tarnowski M, Schneider G, Amann G, Clark G, Houghton P, Barr FG, Kenner L, Ratajczak MZ, Kucia M. RasGRF1 regulates proliferation and metastatic behavior of human alveolar rhabdomyosarcomas. Int J Oncol 2012;41:995-1004. [PMID: 22752028 DOI: 10.3892/ijo.2012.1536] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
15 Wang YH, Xiong J, Wang SF, Yu Y, Wang B, Chen YX, Shi HF, Qiu Y. Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo. Mol Cell Biochem 2010;341:225-33. [PMID: 20376536 DOI: 10.1007/s11010-010-0453-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
16 Faggi F, Chiarelli N, Colombi M, Mitola S, Ronca R, Madaro L, Bouche M, Poliani PL, Vezzoli M, Longhena F, Monti E, Salani B, Maggi D, Keller C, Fanzani A. Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcoma. Lab Invest 2015;95:585-602. [PMID: 25822667 DOI: 10.1038/labinvest.2015.45] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
17 Sharma SP, Kulkarni AP. Non-islet cell tumour hypoglycaemia: A case report. Indian J Anaesth 2016;60:432-3. [PMID: 27330209 DOI: 10.4103/0019-5049.183399] [Reference Citation Analysis]
18 Palmerini E, Benassi MS, Quattrini I, Pazzaglia L, Donati D, Benini S, Gamberi G, Gambarotti M, Picci P, Ferrari S. Prognostic and predictive role of CXCR4, IGF-1R and Ezrin expression in localized synovial sarcoma: is chemotaxis important to tumor response? Orphanet J Rare Dis 2015;10:6. [PMID: 25613038 DOI: 10.1186/s13023-014-0222-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
19 Rezvani G, Lui JC, Barnes KM, Baron J. A set of imprinted genes required for normal body growth also promotes growth of rhabdomyosarcoma cells. Pediatr Res 2012;71:32-8. [PMID: 22289848 DOI: 10.1038/pr.2011.6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 2.3] [Reference Citation Analysis]
20 Huang HJ, Angelo LS, Rodon J, Sun M, Kuenkele KP, Parsons HA, Trent JC, Kurzrock R. R1507, an anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, and EWS/FLI-1 siRNA in Ewing's sarcoma: convergence at the IGF/IGFR/Akt axis. PLoS One 2011;6:e26060. [PMID: 22022506 DOI: 10.1371/journal.pone.0026060] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
21 Morgan SS, Cranmer LD. Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future. Curr Oncol Rep 2011;13:331-49. [PMID: 21633784 DOI: 10.1007/s11912-011-0182-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
22 Cassinelli G, Dal Bo L, Favini E, Cominetti D, Pozzi S, Tortoreto M, De Cesare M, Lecis D, Scanziani E, Minoli L, Naggi A, Vlodavsky I, Zaffaroni N, Lanzi C. Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases. Cancer Lett 2018;415:187-97. [PMID: 29225052 DOI: 10.1016/j.canlet.2017.12.009] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.6] [Reference Citation Analysis]
23 Setsu N, Yamamoto H, Kohashi K, Endo M, Matsuda S, Yokoyama R, Nishiyama K, Iwamoto Y, Dobashi Y, Oda Y. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. Cancer 2012;118:1637-48. [PMID: 21837670 DOI: 10.1002/cncr.26448] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.7] [Reference Citation Analysis]
24 Zhan XK, Zhang S, Cao BW, Wang JW, Li JL, Sun YK, Zhang W, Yang L, Zhou AP, Chi YH, Li YX, Ma JH, Li CL. Clinicopathological characteristics and treatment outcomes of Chinese patients with genitourinary embryonal rhabdomyosarcoma. World J Surg Oncol 2015;13:190. [PMID: 26018798 DOI: 10.1186/s12957-015-0574-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
25 De Giovanni C, Landuzzi L, Nicoletti G, Lollini P, Nanni P. Molecular and cellular biology of rhabdomyosarcoma. Future Oncology 2009;5:1449-75. [DOI: 10.2217/fon.09.97] [Cited by in Crossref: 71] [Cited by in F6Publishing: 64] [Article Influence: 5.5] [Reference Citation Analysis]
26 Nanni P, Nicoletti G, Landuzzi L, Croci S, Murgo A, Palladini A, Antognoli A, Ianzano ML, Stivani V, Grosso V, Maira SM, García-Echeverría C, Scotlandi K, De Giovanni C, Lollini PL. High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy. Eur J Cancer 2010;46:659-68. [PMID: 20031388 DOI: 10.1016/j.ejca.2009.11.018] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
27 Schott C, Shah AT, Sweet-Cordero EA. Genomic Complexity of Osteosarcoma and Its Implication for Preclinical and Clinical Targeted Therapies. Adv Exp Med Biol 2020;1258:1-19. [PMID: 32767231 DOI: 10.1007/978-3-030-43085-6_1] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Guenther MK, Graab U, Fulda S. Synthetic lethal interaction between PI3K/Akt/mTOR and Ras/MEK/ERK pathway inhibition in rhabdomyosarcoma. Cancer Lett 2013;337:200-9. [PMID: 23684925 DOI: 10.1016/j.canlet.2013.05.010] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 5.0] [Reference Citation Analysis]
29 Lewis MA, Hendrickson AW, Moynihan TJ. Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA Cancer J Clin 2011;61:287-314. [PMID: 21858793 DOI: 10.3322/caac.20124] [Cited by in Crossref: 31] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
30 Bleloch JS, Ballim RD, Kimani S, Parkes J, Panieri E, Willmer T, Prince S. Managing sarcoma: where have we come from and where are we going? Ther Adv Med Oncol 2017;9:637-59. [PMID: 28974986 DOI: 10.1177/1758834017728927] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
31 Lissat A, Chao MM, Kontny U. Targeted therapy in Ewing sarcoma. ISRN Oncol 2012;2012:609439. [PMID: 22690342 DOI: 10.5402/2012/609439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
32 Toretsky JA, Gorlick R. IGF-1R targeted treatment of sarcoma. The Lancet Oncology 2010;11:105-6. [DOI: 10.1016/s1470-2045(09)70391-2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
33 Olanich ME, Barr FG. A call to ARMS: targeting the PAX3-FOXO1 gene in alveolar rhabdomyosarcoma. Expert Opin Ther Targets 2013;17:607-23. [PMID: 23432728 DOI: 10.1517/14728222.2013.772136] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
34 Liang J, Li B, Yuan L, Ye Z. Prognostic value of IGF-1R expression in bone and soft tissue sarcomas: a meta-analysis. Onco Targets Ther 2015;8:1949-55. [PMID: 26251617 DOI: 10.2147/OTT.S88293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.1] [Reference Citation Analysis]
35 Przybyl J, Jurkowska M, Rutkowski P, Debiec-Rychter M, Siedlecki JA. Downstream and intermediate interactions of synovial sarcoma-associated fusion oncoproteins and their implication for targeted therapy. Sarcoma 2012;2012:249219. [PMID: 22550415 DOI: 10.1155/2012/249219] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
36 Yamasaki H, Itawaki A, Morita M, Miyake H, Yamamoto M, Sonoyama H, Tanaka S, Notsu M, Yamauchi M, Fujii Y, Ishikawa N, Fukuda I, Ishihara S, Kanasaki K. A case of insulin-like growth factor 2-producing gastrointestinal stromal tumor with severe hypoglycemia. BMC Endocr Disord 2020;20:60. [PMID: 32393233 DOI: 10.1186/s12902-020-0529-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
37 Wojtalla A, Salm F, Christiansen DG, Cremona T, Cwiek P, Shalaby T, Gross N, Grotzer MA, Arcaro A. Novel agents targeting the IGF-1R/PI3K pathway impair cell proliferation and survival in subsets of medulloblastoma and neuroblastoma. PLoS One 2012;7:e47109. [PMID: 23056595 DOI: 10.1371/journal.pone.0047109] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
38 Ben Nsir A, Boughamoura M, Maatouk M, Kilani M, Hattab N. Dural metastasis of Ewing's sarcoma. Surg Neurol Int 2013;4:96. [PMID: 23956939 DOI: 10.4103/2152-7806.115487] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
39 Hingorani P, Kolb EA. Past, present and future of therapies in pediatric sarcomas. Future Oncol 2010;6:605-18. [PMID: 20373872 DOI: 10.2217/fon.10.19] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Movva S, Verschraegen C. Systemic management strategies for metastatic soft tissue sarcoma. Drugs 2011;71:2115-29. [PMID: 22035513 DOI: 10.2165/11594500-000000000-00000] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
41 Demicco EG, Maki RG, Lev DC, Lazar AJ. New therapeutic targets in soft tissue sarcoma. Adv Anat Pathol 2012;19:170-80. [PMID: 22498582 DOI: 10.1097/PAP.0b013e318253462f] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
42 Halper J. Growth factors as active participants in carcinogenesis: a perspective. Vet Pathol 2010;47:77-97. [PMID: 20080487 DOI: 10.1177/0300985809352981] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
43 Hughes DP. Novel agents in development for pediatric sarcomas. Curr Opin Oncol 2009;21:332-7. [PMID: 19444103 DOI: 10.1097/CCO.0b013e32832c94e2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
44 Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA. Ewing’s Sarcoma: Standard and Experimental Treatment Options. Curr Treat Options in Oncol 2009;10:126-40. [DOI: 10.1007/s11864-009-0104-6] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 6.9] [Reference Citation Analysis]
45 De Giovanni C, Nanni P, Landuzzi L, Ianzano ML, Nicoletti G, Croci S, Palladini A, Lollini PL. Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis. BMC Cancer 2019;19:126. [PMID: 30732578 DOI: 10.1186/s12885-019-5339-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
46 Grymula K, Tarnowski M, Wysoczynski M, Drukala J, Barr FG, Ratajczak J, Kucia M, Ratajczak MZ. Overlapping and distinct role of CXCR7-SDF-1/ITAC and CXCR4-SDF-1 axes in regulating metastatic behavior of human rhabdomyosarcomas. Int J Cancer 2010;127:2554-68. [PMID: 20162608 DOI: 10.1002/ijc.25245] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 6.3] [Reference Citation Analysis]
47 Martins AS, Olmos D, Missiaglia E, Shipley J. Targeting the insulin-like growth factor pathway in rhabdomyosarcomas: rationale and future perspectives. Sarcoma 2011;2011:209736. [PMID: 21437217 DOI: 10.1155/2011/209736] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
48 van Gaal JC, Roeffen MH, Flucke UE, van der Laak JA, van der Heijden G, de Bont ES, Suurmeijer AJ, Versleijen-Jonkers YM, van der Graaf WT. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice. Eur J Cancer 2013;49:3462-70. [PMID: 23867124 DOI: 10.1016/j.ejca.2013.06.022] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
49 Marie PJ. Osteoblast dysfunctions in bone diseases: from cellular and molecular mechanisms to therapeutic strategies. Cell Mol Life Sci 2015;72:1347-61. [PMID: 25487608 DOI: 10.1007/s00018-014-1801-2] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
50 Stefano S, Giovanni S. The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma. Cancers (Basel) 2019;11:E1169. [PMID: 31416195 DOI: 10.3390/cancers11081169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
51 Mao J, Zhuang G, Chen Z. Genetic Polymorphisms of Insulin-Like Growth Factor 1 Are Associated with Osteosarcoma Risk and Prognosis. Med Sci Monit 2017;23:5892-8. [PMID: 29232358 DOI: 10.12659/msm.908004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
52 van de Luijtgaarden AC, Versleijen-Jonkers YM, Roeffen MH, Schreuder HW, Flucke UE, van der Graaf WT. Prognostic and therapeutic relevance of the IGF pathway in Ewing's sarcoma patients. Target Oncol 2013;8:253-60. [PMID: 23292309 DOI: 10.1007/s11523-012-0248-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
53 Kapoor G, Das K. Soft tissue sarcomas in children. Indian J Pediatr. 2012;79:936-942. [PMID: 21935710 DOI: 10.1007/s12098-011-0560-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
54 Boström EA, Svensson M, Andersson S, Jonsson IM, Ekwall AK, Eisler T, Dahlberg LE, Smith U, Bokarewa MI. Resistin and insulin/insulin-like growth factor signaling in rheumatoid arthritis. Arthritis Rheum 2011;63:2894-904. [PMID: 21739426 DOI: 10.1002/art.30527] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 4.3] [Reference Citation Analysis]
55 Ratajczak MZ, Suszynska M, Kucia M. Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer? Clin Transl Med 2016;5:28. [PMID: 27510263 DOI: 10.1186/s40169-016-0113-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
56 Zhu B, Davie JK. New insights into signalling-pathway alterations in rhabdomyosarcoma. Br J Cancer 2015;112:227-31. [PMID: 25211658 DOI: 10.1038/bjc.2014.471] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
57 Palmerini E, Paioli A, Ferrari S. Emerging therapeutic targets for synovial sarcoma. Expert Review of Anticancer Therapy 2014;14:791-806. [DOI: 10.1586/14737140.2014.901155] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
58 van de Luijtgaarden AC, Roeffen MH, Leus MA, Flucke UE, Schreuder BH, van der Graaf WT, Versleijen-jonkers YM. IGF signaling pathway analysis of osteosarcomas reveals the prognostic value of pAKT localization. Future Oncology 2013;9:1733-40. [DOI: 10.2217/fon.13.118] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
59 Gombos A, Metzger-Filho O, Dal Lago L, Awada-Hussein A. Clinical development of insulin-like growth factor receptor--1 (IGF-1R) inhibitors: at the crossroad? Invest New Drugs 2012;30:2433-42. [PMID: 22415797 DOI: 10.1007/s10637-012-9811-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
60 Ahmed AA, Zia H, Wagner L. Therapy resistance mechanisms in Ewing's sarcoma family tumors. Cancer Chemother Pharmacol 2014;73:657-63. [PMID: 24469502 DOI: 10.1007/s00280-014-2392-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
61 Pacioles T, Seth R, Orellana C, John I, Panuganty V, Dhaliwal R. Malignant phyllodes tumor of the breast presenting with hypoglycemia: a case report and literature review. Cancer Manag Res 2014;6:467-73. [PMID: 25525388 DOI: 10.2147/CMAR.S71933] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
62 Weber GF. Molecular Analysis of a Recurrent Sarcoma Identifies a Mutation in FAF1. Sarcoma 2015;2015:839182. [PMID: 25861239 DOI: 10.1155/2015/839182] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
63 Fleuren ED, Versleijen-Jonkers YM, Boerman OC, van der Graaf WT. Targeting receptor tyrosine kinases in osteosarcoma and Ewing sarcoma: current hurdles and future perspectives. Biochim Biophys Acta 2014;1845:266-76. [PMID: 24582852 DOI: 10.1016/j.bbcan.2014.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
64 Somaiah N, von Mehren M. New drugs and combinations for the treatment of soft-tissue sarcoma: a review. Cancer Manag Res 2012;4:397-411. [PMID: 23226072 DOI: 10.2147/CMAR.S23257] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
65 Quesada J, Amato R. The molecular biology of soft-tissue sarcomas and current trends in therapy. Sarcoma 2012;2012:849456. [PMID: 22665999 DOI: 10.1155/2012/849456] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
66 Schmitt T, Kasper B. New medical treatment options and strategies to assess clinical outcome in soft-tissue sarcoma. Expert Review of Anticancer Therapy 2014;9:1159-67. [DOI: 10.1586/era.09.64] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
67 Ahearn TU, Peisch S, Pettersson A, Ebot EM, Zhou CK, Graff RE, Sinnott JA, Fazli L, Judson GL, Bismar TA, Rider JR, Gerke T, Chan JM, Fiorentino M, Flavin R, Sesso HD, Finn S, Giovannucci EL, Gleave M, Loda M, Li Z, Pollak M, Mucci LA; Transdisciplinary Prostate Cancer Partnership (ToPCaP). Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. Carcinogenesis 2018;39:1431-7. [PMID: 30165429 DOI: 10.1093/carcin/bgy112] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
68 Takahashi Y, Kohashi K, Yamada Y, Endo M, Setsu N, Ishii T, Yamamoto H, Iwamoto Y, Oda Y. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas. Hum Pathol 2014;45:984-93. [PMID: 24746202 DOI: 10.1016/j.humpath.2013.12.012] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
69 Olmos D, Postel-Vinay S, Molife LR, Okuno SH, Schuetze SM, Paccagnella ML, Batzel GN, Yin D, Pritchard-Jones K, Judson I, Worden FP, Gualberto A, Scurr M, de Bono JS, Haluska P. Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Lancet Oncol 2010;11:129-35. [PMID: 20036194 DOI: 10.1016/S1470-2045(09)70354-7] [Cited by in Crossref: 247] [Cited by in F6Publishing: 141] [Article Influence: 19.0] [Reference Citation Analysis]
70 Scheipl S, Froehlich EV, Leithner A, Beham A, Quehenberger F, Mokry M, Stammberger H, Varga PP, Lazáry A, Windhager R, Gattenloehner S, Liegl B. Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study: IGF-1R, IGF-1 and IGF-2 in chordomas. Histopathology 2012;60:999-1003. [DOI: 10.1111/j.1365-2559.2012.04186.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
71 Beltran PJ, Chung YA, Moody G, Mitchell P, Cajulis E, Vonderfecht S, Kendall R, Radinsky R, Calzone FJ. Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models. J Pharmacol Exp Ther 2011;337:644-54. [PMID: 21385891 DOI: 10.1124/jpet.110.178400] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 4.9] [Reference Citation Analysis]
72 Movva S. Emerging therapies for sarcoma. Curr Probl Cancer 2013;37:87-101. [PMID: 23719333 DOI: 10.1016/j.currproblcancer.2013.03.004] [Reference Citation Analysis]
73 Nielsen TO, West RB. Translating gene expression into clinical care: sarcomas as a paradigm. J Clin Oncol 2010;28:1796-805. [PMID: 20194847 DOI: 10.1200/JCO.2009.26.1917] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
74 Zhang Y, Wang C. Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells. Oncogene 2011;30:3549-62. [PMID: 21423212 DOI: 10.1038/onc.2011.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
75 Fleuren ED, Versleijen-Jonkers YM, van de Luijtgaarden AC, Molkenboer-Kuenen JD, Heskamp S, Roeffen MH, van Laarhoven HW, Houghton PJ, Oyen WJ, Boerman OC, van der Graaf WT. Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. Clin Cancer Res 2011;17:7693-703. [PMID: 22038993 DOI: 10.1158/1078-0432.CCR-11-1488] [Cited by in Crossref: 34] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
76 Tarnowski M, Tkacz M, Zgutka K, Bujak J, Kopytko P, Pawlik A. Picropodophyllin (PPP) is a potent rhabdomyosarcoma growth inhibitor both in vitro and in vivo. BMC Cancer 2017;17:532. [PMID: 28793874 DOI: 10.1186/s12885-017-3495-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
77 Dickerson EB, Marley K, Edris W, Tyner JW, Schalk V, Macdonald V, Loriaux M, Druker BJ, Helfand SC. Imatinib and Dasatinib Inhibit Hemangiosarcoma and Implicate PDGFR-β and Src in Tumor Growth. Transl Oncol 2013;6:158-68. [PMID: 23544168 DOI: 10.1593/tlo.12307] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
78 Zhu L, McManus MM, Hughes DP. Understanding the Biology of Bone Sarcoma from Early Initiating Events through Late Events in Metastasis and Disease Progression. Front Oncol 2013;3:230. [PMID: 24062983 DOI: 10.3389/fonc.2013.00230] [Cited by in Crossref: 37] [Cited by in F6Publishing: 48] [Article Influence: 4.1] [Reference Citation Analysis]
79 Eid JE, Garcia CB. Reprogramming of mesenchymal stem cells by oncogenes. Semin Cancer Biol 2015;32:18-31. [PMID: 24938913 DOI: 10.1016/j.semcancer.2014.05.005] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
80 Broadhead ML, Clark JC, Myers DE, Dass CR, Choong PF. The molecular pathogenesis of osteosarcoma: a review. Sarcoma 2011;2011:959248. [PMID: 21559216 DOI: 10.1155/2011/959248] [Cited by in Crossref: 182] [Cited by in F6Publishing: 182] [Article Influence: 16.5] [Reference Citation Analysis]
81 George B, Bresson D, Bouazza S, Froelich S, Mandonnet E, Hamdi S, Orabi M, Polivka M, Cazorla A, Adle-Biassette H, Guichard JP, Duet M, Gayat E, Vallée F, Canova CH, Riet F, Bolle S, Calugaru V, Dendale R, Mazeron JJ, Feuvret L, Boissier E, Vignot S, Puget S, Sainte-Rose C, Beccaria K. [Chordoma]. Neurochirurgie 2014;60:63-140. [PMID: 24856008 DOI: 10.1016/j.neuchi.2014.02.003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
82 Rüping K, Altendorf-Hofmann A, Chen Y, Kampmann E, Gibis S, Lindner L, Katenkamp D, Petersen I, Knösel T. High IGF2 and FGFR3 are associated with tumour progression in undifferentiated pleomorphic sarcomas, but EGFR and FGFR3 mutations are a rare event. J Cancer Res Clin Oncol 2014;140:1315-22. [PMID: 24804818 DOI: 10.1007/s00432-014-1700-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
83 Van Arsdale AR, Arend RC, Cossio MJ, Erickson BK, Wang Y, Doo DW, Leath CA, Goldberg GL, Huang GS. Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Med 2018;7:616-25. [PMID: 29455465 DOI: 10.1002/cam4.1335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
84 Reed N. A review of treatment of uterine leiomyosarcomas. Curr Oncol Rep 2013;15:581-7. [PMID: 24136566 DOI: 10.1007/s11912-013-0350-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
85 Maki RG. Ifosfamide in the Neoadjuvant Treatment of Osteogenic Sarcoma. JCO 2012;30:2033-5. [DOI: 10.1200/jco.2012.42.3285] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
86 Fernandes I, Melo-Alvim C, Lopes-Brás R, Esperança-Martins M, Costa L. Osteosarcoma Pathogenesis Leads the Way to New Target Treatments. Int J Mol Sci 2021;22:E813. [PMID: 33467481 DOI: 10.3390/ijms22020813] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
87 Wagner MJ, Maki RG. Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. Front Oncol 2013;3:9. [PMID: 23383402 DOI: 10.3389/fonc.2013.00009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
88 Kuijjer ML, Peterse EF, van den Akker BE, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O, Hassan AB, Hogendoorn PC, Cleton-Jansen AM. IR/IGF1R signaling as potential target for treatment of high-grade osteosarcoma. BMC Cancer 2013;13:245. [PMID: 23688189 DOI: 10.1186/1471-2407-13-245] [Cited by in Crossref: 54] [Cited by in F6Publishing: 52] [Article Influence: 6.0] [Reference Citation Analysis]
89 Kolb EA, Gorlick R. Development of IGF-IR Inhibitors in Pediatric Sarcomas. Curr Oncol Rep 2009;11:307-13. [PMID: 19508836 DOI: 10.1007/s11912-009-0043-1] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
90 Harwood JL, Alexander JH, Mayerson JL, Scharschmidt TJ. Targeted Chemotherapy in Bone and Soft-Tissue Sarcoma. Orthop Clin North Am 2015;46:587-608. [PMID: 26410647 DOI: 10.1016/j.ocl.2015.06.011] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
91 Maki RG. Small is beautiful: insulin-like growth factors and their role in growth, development, and cancer. J Clin Oncol. 2010;28:4985-4995. [PMID: 20975071 DOI: 10.1200/jco.2009.27.5040] [Cited by in Crossref: 148] [Cited by in F6Publishing: 76] [Article Influence: 12.3] [Reference Citation Analysis]
92 Arora RS, Alston RD, Eden TO, Geraci M, Birch JM. The contrasting age-incidence patterns of bone tumours in teenagers and young adults: Implications for aetiology. Int J Cancer 2012;131:1678-85. [PMID: 22174047 DOI: 10.1002/ijc.27402] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
93 Tang Y, Wu J, Zhang Y, Ju L, Qu X, Jiang D. Magnetic transfection with superparamagnetic chitosan-loaded IGFBP5 nanoparticles and their in vitro biosafety. R Soc Open Sci 2021;8:201331. [PMID: 33614075 DOI: 10.1098/rsos.201331] [Reference Citation Analysis]
94 Rikhof B, van der Graaf WT, Suurmeijer AJ, van Doorn J, Meersma GJ, Groenen PJ, Schuuring EM, Meijer C, de Jong S. ‘Big’-insulin-like growth factor-II signaling is an autocrine survival pathway in gastrointestinal stromal tumors. Am J Pathol. 2012;181:303-312. [PMID: 22658485 DOI: 10.1016/j.ajpath.2012.03.028] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
95 van der Graaf WT, Gelderblom H. New systemic therapy options for advanced sarcomas. Curr Treat Options Oncol 2012;13:306-17. [PMID: 22661203 DOI: 10.1007/s11864-012-0196-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
96 Cironi L, Provero P, Riggi N, Janiszewska M, Suva D, Suva ML, Kindler V, Stamenkovic I. Epigenetic features of human mesenchymal stem cells determine their permissiveness for induction of relevant transcriptional changes by SYT-SSX1. PLoS One 2009;4:e7904. [PMID: 19936258 DOI: 10.1371/journal.pone.0007904] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.8] [Reference Citation Analysis]